Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Ards
← New Search

Ards

Educational clinical summary of Ards for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is intended for educational purposes and as a comprehensive reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be based on the individual patient's condition, the clinician's judgment, and current best practices. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to patient care.

Ards

Overview

  • Definition: Acute Respiratory Distress Syndrome (ARDS) is a severe form of acute lung injury characterized by acute onset of hypoxemic respiratory failure due to non-cardiogenic pulmonary edema and diffuse alveolar damage. The Berlin Definition (2012) criteria are:
    1. Timing: Onset within 1 week of a known clinical insult or worsening respiratory symptoms.
    2. Imaging: Bilateral opacities on chest X-ray or CT scan, not fully explained by effusions, lobar/lung collapse, or nodules.
    3. Origin of Edema: Respiratory failure not fully explained by cardiac failure or fluid overload. Objective assessment (e.g., echocardiography, elevated brain natriuretic peptide) is required if no risk factor for ARDS is present.
    4. Oxygenation Impairment: Quantified by the ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2), with positive end-expiratory pressure (PEEP) or continuous positive airway pressure (CPAP) ≥ 5 cmH2O:
      • Mild ARDS: 200 mmHg < PaO2/FiO2 ≤ 300 mmHg
      • Moderate ARDS: 100 mmHg < PaO2/FiO2 ≤ 200 mmHg
      • Severe ARDS: PaO2/FiO2 ≤ 100 mmHg
  • Epidemiology:
    • Incidence: Varies widely, but estimated at 10-80 cases per 100,000 person-years, depending on the definition and population studied.
    • Mortality: Significantly high, ranging from 30% for mild ARDS to over 45% for severe ARDS, often due to multi-organ failure.
    • Demographics: Affects all age groups, but incidence and mortality generally increase with age and comorbidities.
  • Classification: Based on the PaO2/FiO2 ratio, as defined in the Berlin Definition: Mild, Moderate, and Severe ARDS.

Pathophysiology

  • Mechanism: ARDS involves an uncontrolled inflammatory response in the lungs leading to diffuse alveolar damage (DAD). This process typically involves:
    1. Exudative Phase (0-7 days): Endothelial and epithelial cell injury, increased alveolar-capillary permeability, leading to protein-rich fluid exudation into the alveoli and interstitium. Neutrophil infiltration, release of pro-inflammatory cytokines (e.g., IL-1β, IL-6, TNF-α), and formation of hyaline membranes.
    2. Proliferative Phase (7-21 days): Attempted repair with proliferation of type II pneumocytes and fibroblasts. Resolution of edema and inflammation may occur, or progression to fibrosis.
    3. Fibrotic Phase (>21 days): Uncontrolled fibroblast proliferation and collagen deposition leading to extensive pulmonary fibrosis, architectural distortion, and impaired gas exchange.
  • Risk Factors: ARDS typically follows a direct or indirect pulmonary insult.
    • Direct Lung Injury:
      • Severe pneumonia (bacterial, viral, fungal) - most common cause
      • Aspiration of gastric contents
      • Pulmonary contusion
      • Near drowning
      • Inhalational injury
      • Fat embolism
    • Indirect Lung Injury:
      • Sepsis (most common non-pulmonary cause)
      • Severe trauma with shock and multiple transfusions
      • Non-pulmonary severe infection (e.g., pancreatitis, peritonitis)
      • Massive transfusion (TRALI - Transfusion-Related Acute Lung Injury)
      • Burns
      • Drug overdose
      • Acute pancreatitis
      • Cardiopulmonary bypass
  • Protective Factors: No specific "protective" factors against ARDS development, but aggressive management of underlying risk factors can reduce incidence or severity.
    • Early and effective treatment of sepsis.
    • Careful fluid management in critically ill patients.
    • Prevention of aspiration in intubated or obtunded patients.
    • Vaccination against common respiratory pathogens (e.g., influenza, pneumococcus).

Clinical Presentation

Signs and Symptoms

  • Cardinal Features:
    • Acute onset of severe dyspnea (shortness of breath).
    • Tachypnea (rapid breathing).
    • Refractory hypoxemia (low blood oxygen levels despite high FiO2).
    • Increased work of breathing (accessory muscle use, retractions).
  • Early Signs:
    • Subtle dyspnea or tachypnea, often initially attributed to the underlying insult.
    • Mild hypoxemia requiring supplemental oxygen.
    • Anxiety, restlessness, or confusion due to hypoxemia.
  • Advanced Signs:
    • Profound dyspnea and respiratory distress.
    • Cyanosis (bluish discoloration of skin/mucosa).
    • Accessory muscle use, intercostal retractions, nasal flaring.
    • Hypotension (due to systemic inflammation or cardiac dysfunction).
    • Multi-organ dysfunction (e.g., acute kidney injury, liver dysfunction).
  • Atypical Presentations:
    • ARDS in patients with pre-existing chronic lung disease, where distinguishing new injury from exacerbation can be challenging.
    • Patients receiving positive pressure ventilation for other reasons, where symptoms might be masked.

Physical Examination

  • Inspection:
    • Obvious signs of respiratory distress: tachypnea, accessory muscle use, nasal flaring, intercostal retractions, inability to speak in full sentences.
    • Cyanosis (lips, nail beds) in severe hypoxemia.
    • Signs of the underlying cause (e.g., fever, signs of infection, trauma).
  • Palpation:
    • Increased tactile fremitus may be present if there is associated consolidation.
    • Tracheal deviation might suggest pneumothorax, a complication.
  • Percussion:
    • Dullness over lung fields, indicating consolidation or fluid.
  • Auscultation:
    • Bilateral crackles (rales), often diffuse, indicating alveolar fluid.
    • Bronchial breath sounds over areas of consolidation.
    • Wheezing or rhonchi may be present if there is bronchoconstriction or airway secretions.
    • Heart sounds may be muffled or reveal signs of right heart strain (e.g., loud P2).

Diagnostic Approach

History Taking

  • Key Questions:
    • Timing of onset: When did respiratory symptoms begin? Was it acute or gradual?
    • Known clinical insult: Is there a predisposing condition within the last 7 days (e.g., sepsis, pneumonia, trauma, aspiration)?
    • Respiratory symptoms: Dyspnea severity, cough (productive or non-productive), chest pain.
    • Comorbidities: Any history of cardiac disease, chronic lung disease, renal failure, or immunosuppression.
    • Medications: Any recent drug use or overdose.
    • Fluid balance: Recent fluid intake, output, signs of fluid overload or dehydration.
  • Red Flags:
    • Rapid progression of dyspnea and hypoxemia requiring increasing oxygen support.
    • Signs of impending respiratory failure (e.g., diminishing respiratory effort, altered mental status, cyanosis).
    • Hemodynamic instability (e.g., hypotension, tachycardia).

Laboratory Tests

  • First-Line:
    • Arterial Blood Gas (ABG): Essential for diagnosis and monitoring. Shows hypoxemia (low PaO2) often with respiratory alkalosis initially (due to tachypnea) progressing to respiratory acidosis (due to fatigue or worsening lung injury).
    • Complete Blood Count (CBC) with differential: May show leukocytosis (infection) or leukopenia (sepsis).
    • Basic Metabolic Panel (BMP): Assess renal function, electrolytes, and acid-base status.
    • Cardiac Biomarkers (e.g., BNP, troponin): To rule out cardiogenic pulmonary edema or myocardial injury. BNP > 500 pg/mL or NT-proBNP > 1000 pg/mL (age-adjusted) suggests cardiac dysfunction, but values can be elevated in ARDS without cardiac failure.
    • Inflammatory markers: C-reactive protein (CRP), procalcitonin (PCT) may be elevated, guiding antibiotic therapy (PCT can help differentiate bacterial from viral causes and guide de-escalation).
    • Cultures: Blood, sputum, urine cultures to identify underlying infection.
  • Confirmatory: No specific lab test confirms ARDS; diagnosis is based on combined clinical, imaging, and oxygenation criteria.
  • Monitoring:
    • Serial ABGs: To assess response to ventilation and oxygenation strategies.
    • Lactate levels: To monitor tissue perfusion and shock.
    • Fluid balance and renal function.

Imaging

  • Recommended:
    • Chest X-ray (CXR):
      • Findings: Bilateral, diffuse alveolar opacities or infiltrates, often patchy or confluent, consistent with pulmonary edema. The opacities are typically symmetric and spare the costophrenic angles.
      • Clinical Utility: Rapidly available, helps confirm the imaging criterion of the Berlin definition. It may show other findings such as pleural effusions (less common in pure ARDS) or pneumothorax.
    • Echocardiography:
      • Clinical Utility: Essential to rule out cardiogenic pulmonary edema (e.g., severe left ventricular dysfunction, valvular disease) and assess right ventricular function (important for prognosis and management in ARDS).
  • Advanced:
    • Chest Computed Tomography (CT) Scan:
      • Findings: More detailed visualization of lung parenchyma. Typical patterns include diffuse, bilateral ground-glass opacities, consolidation (often dependent), and atelectasis. May reveal underlying conditions (e.g., pneumonia, aspiration) or complications (e.g., pneumothorax, pulmonary embolism, fibrosis).
      • Clinical Utility: Not routinely required for ARDS diagnosis but useful for:
        • Differentiating ARDS from other lung conditions.
        • Assessing the extent and heterogeneity of lung injury.
        • Guiding PEEP titration (research setting, not routine).
        • Detecting complications not evident on CXR.
    • Lung Ultrasound:
      • Findings: Bilateral B-lines (lung rockets) indicating interstitial edema, consolidations, and pleural line abnormalities. Pleural effusions may or may not be present.
      • Clinical Utility: Increasingly used at the bedside for rapid assessment of pulmonary edema and to rule out pneumothorax. Can differentiate cardiogenic from non-cardiogenic pulmonary edema (e.g., by assessing cardiac function and venous congestion).

Management

Acute Management

The cornerstone of ARDS management is supportive care, primarily lung-protective mechanical ventilation, and addressing the underlying cause. - Immediate: * Secure Airway and Intubate: If respiratory distress is severe and hypoxemia persists despite high-flow oxygen, or if there is impending respiratory arrest. * Initiate Mechanical Ventilation: Start with a lung-protective ventilation strategy immediately. - Stabilization: * Lung-Protective Ventilation: * Tidal Volume (Vt): 4-8 mL/kg of predicted body weight (PBW). Start at 6 mL/kg PBW and reduce to 4 mL/kg PBW if plateau pressure (Pplat) > 30 cmH2O. PBW calculation: * Male: 50 + 0.91 * (height in cm - 152.4) * Female: 45.5 + 0.91 * (height in cm - 152.4) * Plateau Pressure (Pplat): Keep Pplat ≤ 30 cmH2O. This is the primary safety limit. * Positive End-Expiratory Pressure (PEEP): Titrate PEEP to maintain adequate oxygenation (e.g., SpO2 88-95%) while minimizing overdistension and cardiovascular compromise. Use an ARDSNet PEEP/FiO2 table (higher PEEP for higher FiO2 requirements) or individualized titration strategies (e.g., based on driving pressure, esophageal pressure, or recruitment maneuvers). * Driving Pressure (ΔP = Pplat - PEEP): Aim for ΔP ≤ 15 cmH2O. Lower driving pressure is associated with improved survival. * Respiratory Rate (RR): Adjust to achieve target pH (typically 7.30-7.45). Permissive hypercapnia (PaCO2 > 45 mmHg) is tolerated as long as pH > 7.15-7.20. * FiO2: Use the lowest FiO2 necessary to maintain SpO2 88-95% or PaO2 55-80 mmHg. * Conservative Fluid Management: * After initial resuscitation and stabilization of shock, aim for a negative or even fluid balance. * Strategy: Daily assessment of fluid responsiveness. Discontinue maintenance IV fluids and administer diuretics if fluid overloaded and hemodynamically stable. The goal is to reduce pulmonary edema, as demonstrated in the SAFE and FACTT trials. * Prone Positioning: * Indication: For moderate to severe ARDS (PaO2/FiO2 ≤ 150 mmHg) for at least 12-16 hours per day. * Benefit: Improves oxygenation by redistributing ventilation/perfusion matching, reducing atelectasis, and improving lung homogeneity. Shown to reduce mortality in severe ARDS (PROSEVA trial). * Neuromuscular Blockers (NMBAs): * Indication: For severe ARDS (PaO2/FiO2 ≤ 150 mmHg) to facilitate lung-protective ventilation and reduce patient-ventilator asynchrony. * Agent: Continuous infusion of cisatracurium or atracurium. * Duration: Typically for the first 48 hours (early use of NMBAs for severe ARDS associated with improved survival). * Monitoring: Use train-of-four (TOF) monitoring to guide titration to 1-2 twitches. - Emergency: * Refractory Hypoxemia/Respiratory Failure: Consider rescue therapies. * Extracorporeal Membrane Oxygenation (ECMO): * Indication: Veno-venous (VV-ECMO) for severe, refractory hypoxemia despite maximal conventional support (e.g., PaO2/FiO2 < 80 mmHg for >6 hours, severe acidosis with pH < 7.20, intractable hypercapnia). * Clinical Utility: Provides temporary lung rest. Requires specialized centers and expertise. * Recruitment Maneuvers: Brief, controlled increases in PEEP or inspiratory pressure to open collapsed alveoli. Not routinely recommended but may be considered in specific cases (e.g., post-disconnect from ventilator) if performed carefully and blood pressure is stable.

Chronic Management

  • Pharmacological:
    • Corticosteroids:
      • Controversial: Not routinely recommended for all ARDS patients.
      • Potential role: May be considered in late-phase (fibroproliferative) ARDS or in specific etiologies (e.g., COVID-19 ARDS, organizing pneumonia). Low-dose, prolonged courses (e.g., methylprednisolone 0.5-1 mg/kg/day) have been studied. Early administration (<14 days) and discontinuation when appropriate are crucial.
      • Risks: Increased risk of myopathy, hyperglycemia, infection.
    • Inhaled Pulmonary Vasodilators (e.g., inhaled nitric oxide, epoprostenol):
      • Clinical Utility: Can improve oxygenation transiently but do not improve mortality or duration of mechanical ventilation. Used as a rescue therapy for severe hypoxemia or for assessment of RV function (e.g., if RV failure is prominent).
    • No other specific pharmacological agents are proven to improve outcomes in ARDS. Focus remains on supportive care and treating the underlying cause.
  • Non-pharmacological:
    • Nutrition: Enteral nutrition is preferred over parenteral nutrition, initiated early (within 24-48 hours) to maintain gut integrity and prevent complications.
    • Sedation and Analgesia: Minimize sedation to allow for spontaneous breathing trials and prevent delirium. Use a validated sedation scale (e.g., RASS).
    • Delirium Management: Implement bundles to prevent and manage delirium (e.g., early mobilization, sleep hygiene, minimizing sedatives).
    • Rehabilitation: Early mobilization and physical therapy (even while on mechanical ventilation) are critical to prevent ICU-acquired weakness and improve long-term functional outcomes.
    • Stress Ulcer Prophylaxis: Proton pump inhibitors or H2 blockers for patients at high risk.
    • Venous Thromboembolism (VTE) Prophylaxis: Pharmacological (low molecular weight heparin or unfractionated heparin) or mechanical prophylaxis (sequential compression devices).
  • Monitoring:
    • Daily Assessment: For readiness to wean from mechanical ventilation (e.g., spontaneous breathing trials).
    • Fluid status: Daily fluid balance, weight, and clinical assessment for signs of fluid overload or dehydration.
    • Complications: Vigilance for barotrauma, VAP, critical illness polyneuropathy, DVT, AKI, etc.
    • Psychological support: Screening for and addressing anxiety, depression, and PTSD during recovery.

Treatment Algorithms

  • First-Line (Initial 24-48 hours):
    1. Diagnosis: Confirm ARDS based on Berlin criteria.
    2. Identify and Treat Underlying Cause: (e.g., antibiotics for sepsis/pneumonia, source control).
    3. Lung-Protective Ventilation:
      • Vt 4-8 mL/kg PBW, Pplat ≤ 30 cmH2O.
      • PEEP titration (ARDSNet table or individualized).
      • Target SpO2 88-95%.
    4. Conservative Fluid Strategy: After initial resuscitation.
    5. Sedation: Minimal effective sedation.
    6. VTE and Stress Ulcer Prophylaxis.
  • Second-Line (If PaO2/FiO2 ≤ 150 mmHg despite above):
    1. Prone Positioning: For 12-16 hours daily.
    2. Neuromuscular Blockers: Continuous infusion for up to 48 hours.
    3. Consider Corticosteroids: In specific cases (e.g., COVID-19 ARDS, late-phase fibroproliferative ARDS).
  • Refractory Cases (Persistent PaO2/FiO2 ≤ 80 mmHg, severe acidosis, or intractable hypercapnia despite above):
    1. ECMO (Veno-Venous): Referral to specialized center.
    2. Consider Inhaled Pulmonary Vasodilators: As a rescue therapy for oxygenation.
    3. Recruitment Maneuvers: Individualized and cautious approach.
    4. Consider High-Frequency Oscillatory Ventilation (HFOV) or Airway Pressure Release Ventilation (APRV): While not consistently shown to improve mortality, they may be considered in individual cases by experienced clinicians if conventional strategies fail. (Note: HFOV often not superior to conventional lung-protective ventilation in trials).

Complications

  • Common:
    • Ventilator-Associated Pneumonia (VAP): Due to prolonged mechanical ventilation and impaired host defenses.
    • Barotrauma/Volutrauma: Pneumothorax, pneumomediastinum, subcutaneous emphysema from high airway pressures or tidal volumes.
    • ICU-Acquired Weakness (ICU-AW): Critical illness polyneuropathy and/or myopathy, often prolonged mechanical ventilation and NMBAs.
    • Acute Kidney Injury (AKI): Due to sepsis, hypoperfusion, nephrotoxic drugs, or inflammatory mediators.
    • Cardiac dysfunction: Right ventricular dysfunction due to increased pulmonary vascular resistance.
  • Serious:
    • Multi-Organ Dysfunction Syndrome (MODS): Leading cause of death in ARDS, resulting from systemic inflammation.
    • Disseminated Intravascular Coagulation (DIC): Common in severe sepsis or trauma.
    • Pulmonary Embolism: Due to immobility and hypercoagulable state.
    • Sepsis: If not the primary cause, can develop secondarily.
  • Long-term:
    • Pulmonary Fibrosis: Persistence of restrictive lung disease, reduced diffusion capacity, impaired exercise tolerance.
    • Neurocognitive Impairment: Memory deficits, executive dysfunction, attention problems.
    • Psychological Sequelae: Post-Traumatic Stress Disorder (PTSD), depression, anxiety.
    • Reduced Quality of Life: Persistent physical and emotional symptoms affecting daily activities and return to work.

Prognosis

  • Factors:
    • Severity of ARDS: Mortality increases with increasing PaO2/FiO2 ratio impairment.
    • Age: Older patients have higher mortality.
    • Comorbidities: Pre-existing conditions (e.g., chronic liver disease, immunosuppression, chronic heart failure) worsen prognosis.
    • Underlying Cause: Sepsis-induced ARDS often has a worse prognosis than trauma-induced ARDS.
    • Presence of MODS: Number of failing organs strongly correlates with mortality.
    • Response to Therapy: Early improvement in oxygenation and lung mechanics.
  • Survival:
    • Overall hospital mortality for ARDS ranges from 25-45%.
    • Mild ARDS: ~27%
    • Moderate ARDS: ~32%
    • Severe ARDS: ~45%
    • Survival has improved over time due to lung-protective ventilation and supportive care.
  • Quality of Life:
    • Many survivors experience long-term physical, cognitive, and psychological impairments.
    • Reduced exercise capacity, muscle weakness, and fatigue are common.
    • Persistent dyspnea on exertion.
    • Significant proportion of survivors do not return to their previous functional status or employment.
    • High rates of depression, anxiety, and PTSD.

Prevention

  • Primary: Aimed at preventing the underlying risk factors.
    • Sepsis Management: Early recognition and aggressive management of sepsis to prevent progression to ARDS.
    • Aspiration Prevention: Head of bed elevation (30-45 degrees), judicious use of sedatives, swallow evaluation, careful feeding practices in at-risk patients.
    • Safe Transfusion Practices: Restrictive transfusion strategies, awareness of TRALI (Transfusion-Related Acute Lung Injury).
    • Infection Control: Adherence to infection prevention bundles in hospitals (e.g., hand hygiene, VAP prevention bundles).
    • Smoking Cessation: Reduces risk of pneumonia and overall lung vulnerability.
  • Secondary: Early detection and intervention to limit the severity or progression of ARDS.
    • Close monitoring of patients at high risk (e.g., severe trauma, pancreatitis, high-risk surgery).
    • Early recognition of hypoxemia and respiratory distress.
    • Prompt initiation of supportive care and treatment of the underlying cause.
  • Tertiary: Preventing complications and optimizing recovery in established ARDS.
    • Lung-protective ventilation.
    • Conservative fluid management.
    • Early mobilization and rehabilitation.
    • Prevention of VAP and other nosocomial infections.
    • Psychological support and follow-up.

Special Populations

  • Pediatric:
    • Definition: Pediatric Acute Lung Injury Consensus Conference (PALICC) definition differs from Berlin, using oxygenation index (OI) or oxygen saturation index (OSI) as primary criteria, and requiring new infiltrate.
    • Ventilation: Lung protective strategy remains paramount, but specific parameters may differ. Vt is typically 3-6 mL/kg.
    • PEEP: Titrated to maintain oxygenation and avoid derecruitment.
    • Fluid management: More cautious due to smaller circulating volume.
    • Underlying causes: RSV, pneumonia, sepsis, congenital heart disease are common.
  • Geriatric:
    • Increased Incidence and Mortality: Due to age-related decline in lung function, reduced physiological reserve, and higher prevalence of comorbidities.
    • Atypical Presentation: May present with altered mental status or weakness rather than classic respiratory distress.
    • Complications: Higher risk of delirium, ICU-AW, and long-term functional decline.
    • Management: Lung-protective ventilation is essential. Careful attention to fluid balance, renal function, and medication side effects. Early rehabilitation is crucial.
  • Pregnancy:
    • Causes: Common causes include severe preeclampsia/eclampsia, amniotic fluid embolism, septic abortion, pyelonephritis, pneumonia.
    • Management: Lung protective ventilation still applies. Fetal monitoring is essential. Prone positioning can be safely performed up to late pregnancy, though positioning may require modifications for maternal comfort and fetal safety. ECMO has been successfully used in pregnant patients. Urgent delivery may be necessary if maternal or fetal condition deteriorates.
  • Comorbidities:
    • Chronic Obstructive Pulmonary Disease (COPD)/Asthma: Challenges in distinguishing ARDS from exacerbation. Permissive hypercapnia should be handled cautiously if pre-existing CO2 retention. Lower tidal volumes may be more difficult to achieve due to air trapping.
    • Congestive Heart Failure (CHF): Differentiating cardiogenic pulmonary edema from ARDS can be difficult. Echocardiography and BNP are crucial. Management requires careful fluid balance, avoiding both fluid overload and excessive dehydration that could impair cardiac output.
    • Immunocompromised Patients: Higher risk of infection as a cause of ARDS. May have atypical pathogens. Outcomes tend to be worse due to underlying immune suppression.

Clinical Pearls

  • Diagnostic:
    • Think ARDS in any patient with new or worsening hypoxemia and bilateral infiltrates not explained by heart failure, even if the primary insult seems minor.
    • The Berlin definition is key. Ensure all four criteria are met. Don't forget the PEEP ≥ 5 cmH2O requirement for oxygenation assessment.
    • Rule out cardiogenic pulmonary edema using clinical assessment, BNP, and echocardiography, especially if no clear ARDS risk factor is present.
  • Treatment:
    • Lung-protective ventilation is non-negotiable. Adhere strictly to tidal volume (4-8 mL/kg PBW) and plateau pressure (<30 cmH2O) limits. This is the single most impactful intervention.
    • PEEP is your friend, but balance with hemodynamics. Higher PEEP may improve oxygenation but can reduce cardiac output.
    • Prone early for severe ARDS (PaO2/FiO2 ≤ 150 mmHg). It saves lives. Don't wait.
    • Conservative fluid management is crucial after resuscitation. Avoid fluid overload.
    • Treat the underlying cause aggressively. ARDS is a syndrome, not a disease.
  • Pitfalls:
    • Over-reliance on FiO2: Focusing solely on SpO2/PaO2 without considering mechanical parameters (Vt, Pplat, ΔP) can lead to lung injury.
    • Delayed recognition: Missing early signs of ARDS can lead to worse outcomes.
    • Aggressive fluid resuscitation beyond initial shock stabilization: Can worsen pulmonary edema.
    • Prolonged or unnecessary neuromuscular blockade: Leads to critical illness myopathy/neuropathy.
    • Failure to mobilize patients: Contributes to ICU-AW and prolonged recovery.
    • Neglecting psychosocial aspects: Long-term psychological sequelae are common.

Recent Updates

  • Guidelines:
    • SCCM/ESICM Guidelines for ARDS: Ongoing updates refining recommendations for ventilation, adjunctive therapies, and ECMO. Emphasize early lung-protective ventilation, prone positioning for severe ARDS, and conservative fluid management.
    • WHO/NIH COVID-19 Treatment Guidelines: Specific recommendations for ARDS in the context of COVID-19, including the use of corticosteroids (e.g., dexamethasone) for hospitalized patients requiring supplemental oxygen, including those with ARDS.
  • Evidence:
    • Corticosteroids in COVID-19 ARDS: The RECOVERY trial showed a significant mortality benefit with dexamethasone in severe COVID-19, leading to broader acceptance of corticosteroid use in viral ARDS.
    • Driving Pressure: Growing evidence highlights driving pressure (Pplat - PEEP) as a strong predictor of mortality and potentially a target for ventilation optimization, more so than PEEP alone.
    • Early Mobilization: Increasing evidence supporting the benefits of early, progressive mobilization in critically ill patients, including those with ARDS, to mitigate ICU-acquired weakness and improve functional outcomes.
  • Controversies:
    • Optimal PEEP Titration: While ARDSNet PEEP tables are widely used, individualized PEEP strategies (e.g., PEEP based on driving pressure, esophageal pressure, or stress index) are still being researched for their superiority.
    • Role of Biomarkers: Efforts to identify biomarkers that can guide therapy (e.g., subphenotyping ARDS patients for tailored treatment) or predict outcomes are ongoing but not yet integrated into routine clinical practice.
    • Non-invasive Ventilation (NIV) in ARDS: While generally discouraged in moderate-severe ARDS due to high failure rates, its role in mild ARDS or as a bridge to intubation is still debated, with a high risk of delayed intubation and worse outcomes. High-flow nasal cannula (HFNC) is increasingly used in mild ARDS but requires close monitoring.

Key References

  • Guidelines:
    • ARDS Definition: Ranieri VM, Rubenfeld G, Thompson BT, et al. Acute Respiratory Distress Syndrome: The Berlin Definition. JAMA. 2012;307(23):2526-2533.
    • Mechanical Ventilation: The Acute Respiratory Distress Syndrome Network. Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. N Engl J Med. 2000;342(18):1301-1308.
    • Sepsis Guidelines: Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063-e1143.
  • Studies:
    • Prone Positioning: Guérin C, Reignier J, Richard J-C, et al. Prone Positioning in Severe Acute Respiratory Distress Syndrome. N Engl J Med. 2013;368(23):2159-2168. (PROSEVA trial)
    • Fluid Management: National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of Two Fluid-Management Strategies in Acute Lung Injury. N Engl J Med. 2006;354(24):2564-2575. (FACTT trial)
    • Neuromuscular Blockade: Papazian L, Forel JM, Gacouin A, et al. Neuromuscular Blockers in Early Acute Respiratory Distress Syndrome. N Engl J Med. 2010;363(12):1107-1116.
    • ECMO: Combes A, Hajage D, Capellier G, et al. Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. N Engl J Med. 2018;378(21):1965-1975. (CESAR trial and subsequent meta-analyses informing current practice)
    • Corticosteroids (COVID-19): RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report. N Engl J Med. 2021;384(8):693-704.
  • Reviews:
    • Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. N Engl J Med. 2017;377(6):562-572.
    • Griffiths MJD, et al. The Lancet Respiratory Medicine: The Acute Respiratory Distress Syndrome. Lancet Respir Med. 2019;7(6):535-545.

Disclaimer: This information is intended for educational purposes and as a comprehensive reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions must always be based on the individual patient's condition, the clinician's judgment, and current best practices. Always consult with a qualified healthcare provider for any health concerns or before making any decisions related to patient care.

Dr. Vivek's AI | For Educational Purposes Only